Bevacizumab for Wet Age-Related Macular Degeneration
How Bevacizumab Treats Wet AMD
According to the AAO, bevacizumab was originally FDA-approved for the treatment of metastatic colorectal cancer in 2004 but has never received FDA approval for any ophthalmic indication. Ophthalmologists began using it as an intravitreal injection for wet AMD because it targets the same VEGF-A protein as approved eye medications at a fraction of the cost. According to the AAO, bevacizumab is the most widely used drug for wet AMD in the United States, with approximately half of ophthalmologists prescribing it as first-line therapy.
The landmark CATT trial, sponsored by the NEI and enrolling 1,208 patients at 44 U.S. centers, compared bevacizumab to ranibizumab on the same dosing schedules. According to NEI CATT results, monthly bevacizumab produced visual gains of 8.0 letters at one year compared to 8.5 letters for monthly ranibizumab, demonstrating equivalent effectiveness. At two years, both drugs continued to show similar visual acuity outcomes when given on matching dosing schedules, solidifying bevacizumab as a validated treatment option for wet AMD.
According to NEI CATT two-year results, monthly dosing produced slightly better visual outcomes than as-needed dosing for both medications, confirming that consistent treatment frequency matters regardless of which drug you receive.
According to the AAO, one dose of compounded intravitreal bevacizumab costs approximately $50 to $100 compared to about $1,986 per dose for ranibizumab. This roughly 30-fold cost difference makes bevacizumab the most affordable anti-VEGF option. For patients without comprehensive insurance coverage, for those with high deductibles, or for practices managing large numbers of wet AMD patients, this cost difference can be decisive in determining which treatment is sustainable long-term.
What Treatment Involves
According to the AAO, your retina specialist orders bevacizumab from compounding pharmacies for intravitreal eye use because manufacturers designed the original product for intravenous cancer treatment. The compounding pharmacy repackages the full-strength cancer vial into smaller, single-use aliquots suitable for intravitreal injection. Your retina specialist orders the compounded medication from a pharmacy that follows sterile preparation protocols. You do not need to arrange this yourself.
Like other anti-VEGF injections, bevacizumab is delivered into the vitreous cavity of your eye through a small needle. Your retina specialist numbs your eye with drops, applies antiseptic, and injects the medication in seconds. Most patients feel pressure but not sharp pain during the procedure. Temporary blurry vision, mild floaters, or a gritty sensation after the injection are common and typically resolve within a day or two. Bring a driver to the appointment, and avoid rubbing your eye for the rest of the day.
Most retina specialists start with monthly injections and may transition to treat-and-extend or PRN dosing based on your OCT imaging response. Your retina specialist gives bevacizumab on a monthly or near-monthly schedule because it clears from the eye faster than some newer agents. Your doctor monitors your retina with OCT imaging at every visit to determine whether the current interval provides adequate disease control. If fluid persists despite consistent dosing, your retina specialist may switch you to a different anti-VEGF agent or adjust your treatment approach.
Safety Considerations
Temporary blurred vision, mild discomfort, redness on the white of the eye, and small floaters are common after any intravitreal injection. These effects resolve within a few days. A brief rise in eye pressure right after the injection is monitored by your doctor before you leave the office.
According to CATT two-year results (NEJM, 2012), serious adverse events occurred at a rate of 40 percent for bevacizumab versus 32 percent for ranibizumab over two years. However, clinical interpretation of this difference is debated because many of these events were non-ocular (not related to the eye). Injection-related eye complications, such as endophthalmitis, occurred at similarly low rates for both drugs.
According to ASRS (October 2024), the largest supplier of repackaged bevacizumab for retina practices announced cessation of production in October 2024, causing significant supply disruptions for practices across the country that relied on compounded bevacizumab as their primary wet AMD treatment. If compounded bevacizumab is not available at your treatment center, your retina specialist can switch you to an approved anti-VEGF medication. Ask your doctor's office about current availability before your next appointment.
Contact your retina specialist the same day if you develop increasing eye pain, sudden vision loss, new heavy floaters, flashes of light, or light sensitivity after an injection. These symptoms can indicate endophthalmitis or retinal detachment. Early treatment of these rare but serious complications preserves your remaining vision and prevents permanent damage.
Questions About Bevacizumab for Wet AMD
Off-label use means the drug is FDA-approved for a different condition but has been studied extensively for wet AMD. The CATT trial, one of the largest eye treatment studies ever conducted, confirmed bevacizumab's effectiveness and safety profile for wet AMD. The ophthalmology community widely accepts its use based on this evidence.
Cost is the primary reason. Bevacizumab delivers equivalent visual outcomes to ranibizumab at roughly one-thirtieth the price. For patients with high copays, limited insurance, or practices treating many AMD patients, bevacizumab makes the same quality of care accessible at a sustainable cost.
Compounding pharmacies that supply bevacizumab for retina practices prepare the medication under sterile conditions following FDA-regulated standards for compounded sterile preparations. However, compounding introduces a preparation step that manufactured single-use products do not require. Your retina specialist works with pharmacies that meet high quality standards. FDA efforts to approve a dedicated ophthalmic bevacizumab formulation are ongoing.
Supply disruptions have affected some practices. If compounded bevacizumab is unavailable, your retina specialist can switch you to aflibercept, ranibizumab, faricimab, or their biosimilars. All provide effective wet AMD treatment. Your doctor will choose the best available alternative based on your clinical needs and insurance coverage.
Bevacizumab is typically given monthly or near-monthly because it may clear from the eye faster than newer agents like aflibercept or faricimab. Patients who prefer less frequent injections may discuss switching to a medication that supports longer intervals. Your retina specialist adjusts the schedule based on your OCT imaging findings at each visit, looking for fluid beneath or within your retina that indicates the drug has worn off.
Clinical trials for an FDA-approved ophthalmic bevacizumab formulation are ongoing. If approved, this product would provide a standardized, single-use formulation designed specifically for eye injection, potentially addressing compounding-related supply and quality concerns. Your retina specialist can update you on regulatory progress and availability as it evolves over the coming months.
Talk to Your Doctor About Your Options
Bevacizumab offers effective wet AMD treatment at the lowest cost of any anti-VEGF option. Discuss availability, safety, and how bevacizumab fits into your treatment plan with your retina specialist to make an informed choice about your care.